Eduard joined Anaveon from Innovent Biologics (USA), Inc. where he served as CMO and President and was responsible for the clinical development strategy and execution outside of China. Prior to that he was Executive Director and Global Program Clinical Head at Novartis leading the cross functional clinical team for the melanoma, and prostate cancer franchise with main accountability for a large clinical development program consisting of more than 25 clinical studies (Phase I to Phase III) with targeted and immune-oncology compounds. Previously he served in roles of increasing responsibility at Amgen and Roche. Eduard has accumulated a wealth of experience across all aspects of clinical development, clinical operations and medical affairs during his career located in the United States and Switzerland, and has helped to bring several high-profile oncology drugs to market. He received his Master’s Degree and Medical Doctor Degree in Human Medicine from the University of Zurich in Switzerland.
Search here
Categories
Recent Posts
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual Meeting
June 5, 2023Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
June 3, 2023Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting
April 18, 2023
Popular Tags
Archives
- June 2023 2
- April 2023 1
- March 2023 2
- February 2023 1
- November 2022 2
- October 2022 1
- September 2022 1
- July 2022 3
- April 2022 1
- March 2022 1
- December 2021 1
- November 2021 1
- June 2021 1
- March 2021 1
- November 2020 1
- May 2020 1
- April 2019 1
- February 2019 1